CONVERGE
vergelabs.com
- Web
6.1 Club score Visit vergelabs.com
What the maker publishes
- Commercial access
- Verge describes engagement models ranging from full target-discovery campaigns to focused human-relevance assessments. source
- Company
- Verge Labs says it started as Verge Genomics in 2015 and became Verge Labs in 2026. source
- Data collection
- VergeDB is built from brain tissue partnerships and includes transcriptomic, genetic, clinical, and multi-omics data. source
- Founded
- 2015 source
- Headquarters
- San Francisco, California source
- Model
- Its model infers an individual patient's brain molecular state from a routine blood draw and predicts drug response. source
- Product
- CONVERGE is an AI operating system for neuroscience drug development combining foundation models and systems-biology workflows. source
- Program enablement
- CONVERGE helps teams evaluate target pathways, patient subgroups, preclinical models, and indication opportunities. source
- Scale
- The company's platform data page reports 12,000 brain transcriptomes, 6,000+ neurological patients and controls, and 15M single-cell profiles. source
- Security and integrations
- The opened official product pages do not state security certifications or third-party integrations. source
- Support
- Verge says it aims to reply to platform and partnership inquiries within two business days. source
- Target discovery
- The platform identifies disease signatures and targets using multimodal patient data and human tissue and genetics. source
- Training data
- The foundation model is trained on proprietary multimodal CNS patient data and can be tuned with program- and trial-specific data. source
- Trial optimization
- It stratifies trial populations by molecular endotype and identifies likely-benefit subgroups and pharmacodynamic biomarkers. source
- Users
- The product is presented for drug developers working on neuroscience and CNS programs. source
Checked against the maker's pages on 14 Nov 2026.